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Introduction
In recent years, extensive research activity has been devoted 
to the study of pluripotency transcription factors (TFs). Oct4 
(POU5F1) encodes a homeodomain-containing TF essential for 
the establishment and maintenance of self-renewal and pluri-
potency.1 Oct4 binds specific sequences of DNA through coop-
erative interactions with other TFs, such as Sox2. These TF-TF 
interactions provide context-dependent combinatorial oppor-
tunities and binding epitopes for activator complexes, repressor 
complexes and chromatin remodelers.2-5 Genes upregulated by 
Oct4 include transcriptional partners involved in self-renewal, 
such as Sox2 and Nanog. In embryonic stem cells (ESCs), the 
TFs Oct4, Sox2 and Nanog form a feed forward auto-regulatory 
feedback loop, which results in activation of self-renewal, while 
repressing differentiation gene programs.6,7
Differentiation of ESCs is critically controlled by epigenetic 
mechanisms, notably DNA methylation and histone methylation 
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(H3K9me). Incorporation of DNA methylation in the Oct4 
promoter, catalyzed by de novo methyltransferases Dnmt3a 
and Dnmt3b, is considered a critical and “irreversible” epigen-
etic switch, which forces ESCs to differentiate.8,9 Hence, the 
vast majority of somatic cells, such as fibroblasts, retain a meth-
ylated and silenced Oct4 promoter. In contrast, this gene has 
been reported to be expressed in some stem cells, such as ESCs, 
stem cells of the germinal line,10 and more recently, breast-milk-
derived stem cells.11 In addition, overexpression of Oct4 has been 
associated with oncogenic processes in several malignancies, such 
as breast12 and ovarian cancers.13,14
Given the principal role of Oct4 silencing in differentiation, 
cell engineering and cancer, novel molecular strategies to revert 
this epigenetic state are of significant interest. The endogenous 
Oct4 promoter is commonly reactivated by exogenous delivery of 
specific cDNA combinations, including the Oct4, Sox2, Klf4 and 
c-Myc cDNAs, in a process referred as reprogramming to pluri-
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domain was a potent upregulation of the endogenous gene 
achieved. The potency of the ZFP was dependent on the cell line 
analyzed, which suggests that the genomic microenvironment 
critically influences the regulatory outcome of KRAB-ZFPs. In 
some ovarian cancer cell lines, the activation of Oct4 mediated by 
the ZFP was similar to the levels of activation achieved by ectopic 
cDNA delivery. Our results indicate that ZFPs linked to KRAB 
domains can function, in specific chromatin contexts, as potent 
activators of silenced genes. Our studies support a new paradigm 
for the study of KRAB-ZFPs, and for the design of artificial acti-
vators in epigenetic reprogramming and cancer therapeutics.
Results
Oct4 silencing in a panel of breast and ovarian cancer samples. 
We first examined the levels of expression of Oct4 and two of 
its self-renewal TF targets, Sox2 and Nanog, in a panel of breast 
and ovarian cancer cell lines and tissue specimens by quantita-
tive real-time PCR (qRT-PCR, Fig. 1A and C). As expected, we 
found Oct4, Sox2 and Nanog silenced in primary cell lines such 
as human dermal fibroblasts, human mammary epithelial cells 
(HMECs) and non-transformed, immortalized breast epithe-
lial cell lines, such the MCF-12A line. In contrast, all three TFs 
were abundantly expressed in hESCs and in the teratoma cell 
line NT2/D1, as expected from a positive auto-regulatory feed-
back loop reported between Oct4, Sox2 and Nanog in stem cells 
(Fig. 1A).6 p86-OCBT-L1 is a breast cancer cell line generated 
by overexpression of hOct4 cDNA followed by serial passaging 
of breast epithelial cells from a mammoplastic donor (p86).12 
These cells acquired tumor-initiating features and re-activated 
the endogenous Oct4 and Nanog mRNAs,12 and were thus used 
as a positive control in the cancer cell line panel.
In breast and ovarian cancer samples, heterogeneous portraits 
of mRNA upregulation were observed, with no overall correla-
tion between Oct4, Sox2 and Nanog transcript levels in the can-
cer cells. These data clearly demonstrated aberrant regulation 
of Oct4, Sox2 and Nanog mRNA expression in the tumor cells 
relative to somatic cell lines. Some breast cancer lines, such as 
MCF7, exhibited very high levels of Sox2, which were compa-
rable with those observed in hESCs. In the vast majority of breast 
cancer lines examined both, Oct4 and Nanog mRNA levels were 
at least two orders of magnitude lower than hESCs and only 
~10-fold higher than those detected in non-transformed cells. In 
contrast with breast cancer cell lines, some ovarian cancer lines 
and cell lines derived from ascites isolated from serous epithelial 
ovarian cancer (SOC) patients abundantly expressed Oct4, Sox2 
and Nanog, with the highest expression of Oct4 detected in the 
PA-1 line (Fig. 1B). The Oct4, Sox2 and Nanog mRNA expres-
sion was further validated in a panel of tissue specimens isolated 
from SOC patients, which revealed high levels of pluripotency 
TFs in some primary tumor tissue and in less extent in abdomi-
nal metastases isolated from the same patients (Fig. S1A). The 
expression of Oct4 in breast and ovarian cell lines and in some 
SOC tumor specimens was verified by immunofluorescence (IF) 
and immunohistochemistry (IHC), revealing predominantly a 
nuclear protein distribution. Moreover, some ovarian cancer cell 
to pluripotency was elegantly demonstrated by the generation of 
induced pluripotent cells by a single delivery of Oct4 cDNA in 
neural stem cells.17 Moreover, it is well recognized that the bot-
tleneck of the reprogramming process involves the re-activation 
and de-silencing of the endogenous pluripotency factors.18 
However, the exogenous expression of cDNAs often entails an 
incomplete erasure of the epigenetic memory of the cell of origin, 
resulting in incomplete reprogramming of CG methylation and 
other histone modifications, together with an aberrant epigen-
etic signature, which is transmitted in differentiated iPS cells.19,20 
The erasure of epigenetic silencing marks can be facilitated by 
a combination of cDNAs and small molecules,21 particularly 
chromatin remodeling agents, such as DNA methyltransfer-
ase, H3K9-methyltransferase and histone deacetylase (HDAC) 
inhibitors.22,23 In the last few years, several enzymatic activities 
associated with DNA demethylation have been identified in 
ESCs and these shown to play a role in early events of repro-
gramming.24,25 More recently, sequence-specific engineered pro-
teins, Transcription Activator Like effectors (TALEs), have been 
designed to reactivate pluripotency genes, such as Sox2,22 Klf422 
and Oct4,26 in somatic cells. While Oct4-specific TALEs are not 
capable of upregulating the endogenous gene, combinations of 
TALEs with chromatin remodelers have been shown to reactivate 
the Oct4 promoter, outlining the importance of genomic silenc-
ing as an epigenetic blockade for artificial regulation.26
In addition to TALEs, engineered zinc finger (ZF) proteins 
(ZFPs) or artificial transcription factors (ATFs), represent an 
alternative strategy to modulate the epigenetic state of targeted 
promoters.27,28 In contrast with TALEs, ZFPs are generated 
from mammalian SP1 backbones, which have the advantage to 
bind with high affinity CG rich sequences abundantly repre-
sented in proximal promoters.29 Some designer ZFPs have been 
shown to reactivate the tumor suppressor gene mammary serine 
protease inhibitor (maspin) in cell lines carrying a high density 
of methylated CpG di-nucleotides.30-34 In addition to methyl-
ated tumor suppressors, 6ZF arrays targeting 18-base pair (bp) 
sites in promoters have been shown to bind and regulate a large 
spectrum of cellular targets. Moreover, like their natural coun-
terparts, artificial ZFP require specific activators and repressor 
domains to promote differential expression of targeted genes.35,36 
More recently, we have described nearly 95% repression of Sox2 
via ZFP attached to a Kruppel associated Box (KRAB or SKD 
domain37) and ~60% repression with the same ZFPs linked to 
a Dnmt3a catalytic domain,38 in breast cancer cells. KRAB-
containing ZFPs are traditionally regarded as potent transcrip-
tional repressors via KAP-1-mediated recruitment of Histone 
deacetylase NuRD complex, Histone deacetylases (HDACs), his-
tone methyltransferase SETDB1 and heterochromatin protein 1 
(HP1).39,40 In addition to their role as transcriptional repressors, 
emerging work on natural ZFPs by genome-wide ChIP-Seq map-
ping suggest that at certain loci some KRAB-containing ZFPs, 
such as ZFN263,41 could function to activate endogenous genes.
In this manuscript, we describe the construction of a designer 
ZFP composed of 6ZF domains, able to reactivate the endog-
enous Oct4 promoter in a panel of cell lines carrying a silenced 
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DNA-binding domain (ZF-119) with a panel of effector 
domains: (1) the N-terminal Herpes Virus 16 (VP16), which 
functions as transcriptional activator by recruiting the mediator 
protein, (2) the C-terminal VP64, which is a tetramer of VP16 
engineered in the C-terminus of artificial ZFPs to upregulate tar-
get gene expression47 and (3) the Kruppel associated box (KRAB 
domain), which is located in the N-terminus of several natural 
ZF-containing proteins, and typically functions as a repressor 
domain.48,49 In addition, as controls, we took advantage of the 
catalytic domain of the DNA-methyltransferase 3a (Dnmt3a), 
which was positioned either in the N- or C-terminal end of 
ZF-119. In both configurations (N- and C-terminal fusions), the 
Dnmt3a catalytic domain has been shown to effectively silence 
targeted promoters when linked to 6ZF arrays.38 Further, we 
assessed the non-specific regulatory effects of the ZFP by cloning 
non-cognate 6ZF domains designed to bind other sequences of 
the genome (a non-specific 6ZF array and a KRAB-6ZF con-
struct engineered to regulate the maspin promoter (ATF-12631). 
The resulting fusions were cloned in a retroviral vector pMX-
IRES-GFP and retroviral particles were used to infect different 
human cell lines carrying a silenced Oct4 promoter. An Oct4 
cDNA expression vector was used as positive control for the trans-
duction in the different host cell lines and real time expression 
analyses of all the panel constructs was normalized to hESCs. In 
the MDA-MB-231 cell line, the Oct4-specific 6ZFs were able to 
upregulate Oct4 only when linked to the KRAB domain (146.1-
fold over control-transduced cells, which corresponds up to 15% 
of the amount of Oct4 mRNA expressed in hESCs). The ZF-119 
(the DNA-binding domain in absence of effector function) and 
the ZF-119 linked to either a N-terminal or C-terminal activators 
were unable to activate the endogenous Oct4 (Fig. 3A). In addi-
tion, both the N- and C-terminal ZF-119-Dnmt3a fusions did 
not significantly modulate Oct4 mRNA expression. The trans-
duction of non-cognate (non-specific 6ZFs) or non-cognate 6ZFs 
linked to the KRAB domain was also un-effective in upregulating 
Oct4 (Fig. 3B). The expression of several 6ZF-effector domain 
fusions was validated by western blotting and immunoprecipita-
tion (Fig. S2 and ref. 32) and by immunofluorescence.38 Overall, 
these results indicated that ZF-119 was able to upregulate Oct4 
only in fusion with the KRAB domain. Moreover, the upregula-
tion of Oct4 by the KRAB-ZF-119 construct was approximately 
one order of magnitude below the exogenous (ectopic) expression 
of the cDNA. In addition to Oct4, the KRAB-ZF-119 construct 
triggered a small but significant upregulation of the downstream 
target of Oct4 Nanog in MDA-MB-231 cells relative to control-
transduced cells (10.7 fold).
In the SUM159 cell line, the upregulation of Oct4 by 
KRAB-ZF-119 was 8 fold over control cells, which represents 
approximately 1% of the mRNA expression in hESCs (Fig. 3C). 
The upregulation of Oct4 in this line was also accompanied 
by significant re-activation of Sox2, and in less extent Nanog 
mRNAs, which could be explained by the feed forward auto-
regulatory feedback loop (transactivation) described between 
Oct4, Sox2 and Nanog TFs in ESCs.6 Interestingly, in another 
silenced Oct4 cell line, OVCAR-3, the KRAB-ZF-119 upregu-
lated both, Oct4 (951.1 fold relative to control, approximately 
lines, such as PA-1 and tumor specimens exhibited some weak 
cytoplasmic staining, which also has been reported by other 
groups14 (Fig. 1C; Fig. S1B). The IF staining of Oct4 in the PA1 
line revealed a high degree of heterogeneity, with high expression 
of the protein observed in a few cells in the population (Fig. 1B).
In ESCs it has been demonstrated that epigenetic regulation 
of the Oct4 promoter, specifically DNA methylation, functions 
as an epigenetic switch, which forces stem cells to differentiate.42 
DNA methylation in the Oct4 promoter has been recognized as 
one of the main blockades for somatic cell reprogramming.43,44 
Unlike somatic cells, such as fibroblasts, both ESCs and iPSCs 
carry a de-methylated Oct4 promoter, which is associated with 
high expression of the endogenous gene. We next studied DNA 
methylation frequencies in the Oct4 promoter, using a Sequenom 
EpiTYPER platform, in the panel of cancer cell lines to examine 
if silencing of Oct4 was also associated with differential DNA 
methylation in the tumor cells. In normal, non-transformed 
mammary epithelial cells, high levels of DNA methylation in 
the Oct4 promoter were observed, with similar frequencies to 
those reported in human dermal fibroblasts. Similarly to somatic 
cells, we found high levels of DNA methylation in tumor cell 
lines carrying silenced Oct4, such the MDA-MB-231 cell line. 
In addition, some CpG di-nucleotides were found differentially 
methylated in tumor cell lines having high levels of expression 
of Oct4, most notably, in the p86-OCBT-L1 line, which had an 
enriched Oct4-expressing cell population. However, the DNA 
methylation frequencies observed in the majority of tumor lines 
were much higher than those reported in ESCs and iPSCs.15,16,18,45 
In summary, these data indicated that the vast majority of breast 
and ovarian cancers examined retained DNA methylation fre-
quencies in the Oct4 promoter. The retention of methylation in 
the PA-1 cell line could be due to the heterogeneous expression 
of the Oct4 protein in the cell population, with a decrease in the 
methylation frequency of one CpG island in the close proximity 
of the transcription start site, which could be critical for gene 
activation (arrow, Fig. 1D). In contrast, the p86-OTBC-L1 line 
was generated by serial selection and expansion of Oct4-positive 
cells, leading to an enrichment of Oct4 expression in the cell 
population. Consistently, this cell line exhibited a concomitant 
decrease in DNA methylation in multiple CpG islands along the 
promoter (arrows, Fig. 1D).
Designer ZFP containing a KRAB domain upregulate Oct4 
in cell lines carrying a methylated promoter. To regulate the 
Oct4 gene promoter, we designed a 6ZFP recognizing an 18-base 
pair (bp) target located in the proximal promoter region at -119 
base pairs upstream the translation start site of the gene. We 
chose this target sequence as it was found perfectly conserved in 
multiple vertebrate species, such as mouse and human, indicat-
ing an important regulatory function.46 In addition, engineered 
ZFPs have been shown to efficiently regulate target genes in the 
close proximity of the translation start site (Fig. 2A). The ZFs 
were constructed by a modular helix grafting method using the 
helical sequences known to interact with each of the correspond-
ing triplets of targeted site (Fig. 2B).
To test the capability of our engineered proteins to regu-
























Figure 1. Differential endogenous expression of Oct4, Sox2 and Nanog in breast and ovarian cell lines. Endogenous Oct4, Sox2 and Nanog mrNA levels 
were assessed by quantitative real-time pCr in a panel of different breast (A) and ovarian (B) cell lines. real-time quantification for each gene was 
normalized to the fibroblast cell samples. hESCs, p86-otBC-L1 and Nt2/D1 cells represented positive controls for Oct4, Sox2 and Nanog expression. 
primary ovarian cancer cell cultures were generated from cells isolated from the ascites of patients with epithelial ovarian cancer. Experiments were 
run in triplicate and data represent the mean ± SD of three independent experiments as determined by the Student’s t-test (*p ≤ 0.01). (C) immuno-
fluorescence (iF) oct4 protein expression and intracellular localization of oct4 in different human cell lines: fibroblasts, human mammary epithelial 
cells (HMEC) and cancer cells: MDA-MB-231 (breast), oVCAr-3 and pA-1 (ovarian) and p86-otBC-L1 (breast) cell lines. (D) Methylation status of Oct4 
promoter in fibroblasts, HMEC, MDA-MB-231 oVCAr-3, pA-1 and p86-oCtB-L1 cell lines. the X-axis represent the nucleotide position relative to 
translation start site, and the Y-axis the percentage of methylation along the Oct4 proximal promoter, assessed with a Sequenom EpitYpEr platform. 
pink arrows indicate specific CpG di-nucleotides where methylation frequencies decreased significantly in the tumor samples relative to the non-
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could upregulate Oct4 either indirectly (e.g., by changing chro-
matin structure) or by physically interacting with its associated 
factors in the promoter. Another possible mechanism of action, 
would involve a negative effect of KRAB-ZF-119 on repressive 
epigenetic regulators, such as Dnmt3a or Dnmt3b, or other tran-
scriptional repressors by KRAB or KRAB-associated proteins, 
a model that has also been proposed in the context of natural 
KRAB-containing ZFs.39,40 It is also important to remark that 
the ZF-119 binding site overlaps with a SP1 site in the 5' of the 
18-bp duplex, and with a putative hormone response element 
(HRE) site in the 3' of the binding site. Thus, it is also possible 
that KRAB-ZF-119 could negatively affect the binding and tran-
scriptional activity of SP1 and/or HR or other associated factors 
in the context of the Oct4 promoter.
Discussion
Oct4 encodes a homeodomain-containing TF, which is essential 
to induce and maintain a pluripotent ES or ES-like state.1 While 
Oct4 is expressed at high levels in ESCs, its promoter undergoes 
several layers of epigenetic silencing in differentiated cells.44 In 
this paper we investigated the capability of engineered ZFPs to 
upregulate the endogenous Oct4 gene in cell lines carrying an 
epigenetically silenced promoter.
First, we examined the expression levels of pluripotency TFs 
Oct4, Sox2 and Nanog in a panel of breast and ovarian cancer 
cell lines. We found that Oct4 and Nanog were transcriptionally 
silenced in the vast majority of the breast cancer cell lines exam-
ined. Sox2 mRNA was expressed in some breast cancer cell lines, 
such as MCF-7 and ZR-75-1. In contrast, the pluripotency TFs 
were abundantly expressed in ovarian cancer cell lines and ovar-
ian cancer cell lines derived from serous ovarian cancer (SOC) 
patients. In a recent report, Oct4 expression was found enriched 
in ascites from ovarian cancer patients that underwent resistance 
to chemotherapy.13 The tissue localization of the Oct4 protein in 
ovarian cancer cell lines and tumor specimens was investigated 
by IF and IHC, respectively. We found that Oct4 was predomi-
nantly nuclear while some cytoplasmic staining was also detected, 
particularly in tumor specimens, in accordance with other recent 
studies.14 The significance of the cytoplasmic staining of Oct4 and 
other homeodomain proteins is not well understood. However, 
protein-protein interactions between homeodomain-containing 
TFs and translation initiation factors have been described outlin-
ing a possible action of these TFs regulating translation and/or 
mRNA transport.51 The lack of expression of Oct4 in breast and 
some ovarian cancer cell lines was associated with DNA methyla-
tion. Moreover, cell lines expressing Oct4, such as PA-1 line, also 
retained DNA methylation frequencies in the promoter. This 
is in contrast with fully reprogrammed cells and ESCs, which 
have an Oct4 promoter free of DNA methylation.15,16,18,45 In gene 
promoters, DNA methylation positively correlates with H3K9me 
and cross-talk mechanisms between these marks have been 
reported via direct interactions between DNA methyltransferases 
and Histone methyltransferase G9a.42,52 Thus, additional layers 
of epigenetic silencing mechanisms are anticipated to act in con-
junction with DNA methylation in the Oct4 promoter context.
75% of the total mRNA detected in hESCs) and in less extent, 
Nanog (136.89 fold relative to control, representing up to 10% of 
the Nanog mRNA in hESCs; Fig. 3D). The lack of significant 
upregulation of Sox2 by KRAB-ZF-119 relative to control could 
be explained by the high levels of expression of this gene in this 
particular cell line (Fig. 1B). The strong upregulation of Oct4 by 
KRAB-ZF-119 in the OVCAR-3 cell line was also validated by 
immunoblotting (Fig. 3E). These data revealed that the endoge-
nous expression levels of Oct4 in the KRAB-ZF-119 cells account 
for approximately 20% of the protein amount detected in NT2/
D1 embryonic teratoma cells (Fig. 3F), which exhibit Oct4 expres-
sion levels comparable to those in hESCs (Fig. 1A). In summary, 
our gene expression analyses demonstrated that KRAB-ZF-119 
was able to upregulate the endogenous Oct4 target in cancer 
cell lines carrying an epigenetically silenced promoter and that 
this re-activation of Oct4 was dependent on both, the KRAB 
effector function and an Oct4-specific (cognate) DNA-binding 
domain. To test whether more distally designed KRAB-ZF pro-
teins could similarly upregulate the Oct4 promoter, we designed 
a second protein binding an 18-bp site located 395-bp upstream 
the translation start site. This more distally designed ZF protein 
was unable to reactivate Oct4 when attached to a KRAB or other 
effector domains (Fig. S3). These results outline the importance 
of the precise positioning of the engineered ZF-binding site in the 
endogenous proximal promoter for effective regulation of Oct4.
The phenotypical consequences of Oct4 upregulation were 
consistent with previously published reports, which suggest that 
Oct4 increases the expansion of a poorly differentiated stem 
cell-like population.12,50 As expected, both Oct4 cDNA and in 
less extent KRAB-ZF-119, were able to dramatically induce the 
formation of compact self-renewal spheroids or tumorspheres in 
the OVCAR-3 cell line, over control-transduced cells (Fig. 3G 
and H). Tumorsphere formation assays monitor the capability 
of single cells to proliferate in low adherence plates, and is an in 
vitro assessment of stemness and tumorigenic potential.
Subsequently, in vivo chromatin immunoprecipitation (ChIP) 
experiments were performed to physically demonstrate a direct 
association between the ZF-119 and its cognate site in the Oct4 
promoter. The ZF-119 expression construct was engineered with 
a C-terminal Human influenza hemagglutinin (HA) tag, which 
allowed the immunoprecipitation of the ZF-119-DNA complexes 
in transduced cells. We chose the SUM159 line in these experi-
ments since these cells were highly proliferative and permitted the 
collection of high number of cells (> 105 cells) required for ChIP 
experiments. The ChIP elutes from either control or ZF-119-
transduced cells were amplified using specific primers flanking 
the ZF-119 binding site. As shown in Figure 4A, a specific ChIP 
product was amplified in cells transduced with ZF-119 but not in 
control-transduced cells, indicating that ZF-119 was binding its 
cognate site in the Oct4 promoter.
Putative mechanisms by which the ZF arrays mediate the 
DNA-binding and access to chromatin in the context of a 
silenced Oct4 are outlined in Figure 4B. An N-terminal KRAB 
domain could mediate the activation of Oct4 by facilitating the 
binding of TFs (e.g., Sox2), co-factors and chromatin remodelers, 
























Figure 2. Design of an AtF/Artificial ZFp to upregulate the endogenous Oct4 promoter. (A) Schematic illustration of the Oct4 human promoter outlin-
ing the 18-bp ZF-119 targeted sequence and its location at position -119, relative to the translation start site (first-Met coding AtG triplet, +1). the ZF-
119 sequence was chosen because of the high degree of conservation across vertebrate species, and because of its close proximity to the translation 
start site, which is typically accessible by tFs and nucleosome-free. Numbers designate the distance in bps relative to the start of translation. A puta-
tive binding site for Sp1 is indicated in green; a putative hormone response element (HrE) site is outlined with an open box; the Sox2 binding-site and 
its recognition sequence at position -236 are shown in blue; the Conservative regions Cr1 to Cr4 within the promoter are shown in gray. Conservative 
region 4 (Cr4) contains the binding site for oct4 and Sox2 proteins (red and blue circles and red and blue sequences, respectively). Arrows show the 
orientation of the 18-bp binding site in the promoter (from 5' to 3'). (B) Schematic representation of the ZFps generated in this study. the 6-Zinc Finger 
(ZF) arrays bound to DNA in absence of effector domains are indicated as ZF-119. indicated below is an schematic representation of the different 
constructs, outlining the orientation of the effector domains linked to the ZF-119: KrAB, Vp16, Vp64 (4x Vp16 domain) and Dnmt3a (C) Alphα-helical 
ZF amino acid sequences of ZF-119 engineered to bind their corresponding target DNA triplets (5' to 3'). the helical residues at positions -1, +3 and +6 
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reactivation of either Oct4, Sox2 or Nanog could independently 
occur in the cancer cells to drive oncogenic activation.
Subsequently, we used ZF technology to address the capability 
of artificial DNA binding proteins to re-activate a silenced Oct4 
promoter in cell lines carrying high levels of DNA methylation. 
We constructed an artificial 6ZF protein targeting an 18-base 
pair (bp) site located 119 bps upstream the translation start site. 
Each ZF is a quasi-modular unit that can be engineered to rec-
ognize specific recognition triplets. The ZF-119 site was chosen 
since it was conserved among several vertebrate species, possibly 
reflecting an important function for the regulation of the pro-
moter. Indeed, the ZF-119 targeted site partially overlapped with 
a putative SP1 binding site (5'-GGG GCG GGG-3') in the 5' 
of the 18-bp duplex, and with a Hormone Response Element 
(HRE, 5'-GGC CAG AGG TCA AGG CTA-3') site in the 3' of 
the duplex. The flanking sequences immediately upstream and 
downstream the ZF-119 site contained highly conserved G/G 
rich motifs.46 In addition, a Sox2-binding site was located in the 
proximity (~117 bp) of the ZF-119 binding site.
Previously, we have described artificial ZFPs or artificial tran-
scription factors (ATFs) able to bind and reactivate the tumor 
suppressor mammary serine protease inhibitor (maspin) in lung and 
breast cancer cell lines carrying an epigenetically silenced pro-
moter. The ATFs reactivated maspin only when the 6ZF DNA-
binding domains were linked to an activator domain (VP64).30-32 
The 6ZF-VP64 arrays demonstrated high potency and specificity 
in upregulating maspin, with expression levels similar to exog-
enous maspin cDNA delivery.33
In contrast with maspin, ZF-119 only reactivated Oct4 when the 
6ZFs where linked to a Kruppel associated box (KRAB) domain. 
This result was not initially anticipated since the KRAB domain 
has historically been regarded as transcriptional repressor.48 
Importantly, the potency of the re-activation by KRAB-ZF-119 
was dependent on the cell line analyzed. The highest regula-
tory potential of the protein was found in the OVCAR-3 ovar-
ian cancer cell line, where KRAB-ZF-119 was able to upregulate 
the endogenous Oct4 with mRNA levels approaching 75% of 
those detected in hESCs. This cell line-dependency, in despite 
of the high levels of DNA methylation and gene silencing, sug-
gests that the chromatin microenvironment is different in each 
line, possibly influencing the regulatory potential of the ZFP. For 
Reactivation of Oct4 in breast cancer cells has been associated 
with oncogenesis and tumor initiation.12 Ectopic delivery of Oct4 
cDNA in breast epithelial cells resulted in the reactivation of the 
endogenous gene, which triggered the formation of highly prolif-
erative spheroids or tumorspheres in low adherence plates. These 
Oct4+ cells were able to generate tumors in xenograft models of 
breast cancer and as few as 50 cells gave rise to poorly differen-
tiated, aggressive tumors presenting stem cell-like features and 
colonization capabilities.12 Reciprocally, siRNA-mediated knock-
down of Oct4 and Oct4 targets, such as Nanog, dramatically 
abolished the formation of tumorspheres in vitro12 and induced 
apoptosis of breast cancer cells.53 Likewise, high Oct4 expression 
has been reported in aggressive epithelial ovarian cancers and 
ascites, and has been associated with tumor initiation, chemo-
resistance, unfavorable prognosis and disease recurrence.13,14,54-58 
Our results are consistent with these functions of Oct4 in tumor 
initiation and carcinogenesis. As expected, endogenous Oct4 
upregulation by KRAB-ZF-119 in OVCAR-3 cells dramatically 
induced the formation of compact tumorspheres in non-adherent 
plates, suggesting increased tumorigenic potential.
More recently, Oct4 expression has been detected in breast 
cancers associated with pregnancy and lactation (Hassiotou et al., 
submitted). These pregnancy-associated breast cancers often lack 
the expression of cellular receptors (ER, PR and ErbB2) and are 
associated with poor clinical outcome.59,60 The epigenetic silenc-
ing mechanisms both operating at DNA and at histone level could 
cooperate to ensure that in somatic cells, Oct4 is maintained in 
a repressed state, protecting the cell from oncogenic activation 
and tumor initiation. Our data suggest that some aggressive can-
cers, possibly enriched in tumor initiating cells, express Oct4. 
Re-activation of Oct4 could occur from more differentiated epi-
thelial cells by a partial loss of DNA methylation and possibly 
in conjunction with other histone post-transcriptional modifica-
tions. Alternatively, a pre-existing Oct4+ cancer-stem-cell like 
population could give rise to more differentiated cells acquiring 
de novo DNA methylation and gene silencing. In the vast major-
ity of the tumor samples analyzed, no overall correlation between 
Oct4, Sox2 and Nanog mRNA expression levels was observed. 
This is in contrast with ESCs where a positive feed forward loop 
between these TFs has been proposed, resulting in high expres-
sion of all three TFs. Our results suggest that aberrant epigenetic 
Figure 3 (See opposite page). KrAB-ZF-119 upregulates Oct4 expression in breast and ovarian cancer cell lines. (A–D) Quantification of Oct4, Sox2 and 
Nanog mrNA expression levels by qrt-pCr in MDA-MB-231 (A–B), SUM159 (C) and oVCAr-3 cells (D). X-axis represents the endogenous expression of 
these pluripotency tFs in the un-transfected cell line, together with cells transfected with the different ZFp designs. the Oct4 cDNA was transfected in 
the same pMX vector as positive control for the transfection; Y-axis represents the fold mrNA expression relative to hESCs. the ZFps were retrovirally 
delivered in the cells and total mrNA was extracted for qrt-pCr assays and the results were normalized to hESC samples. Experiments were run in 
triplicate and data represent the mean ± SD of three independent experiments. Statistical significance between samples (e.g KrAB-ZF-119 vs. control) 
was analyzed by the Student’s t-test (***p < 0.0001; **p ≤ 0.01; *p ≤ 0.05). (E) Detection of oct4 protein levels (upper panel) by western blot in oVCAr-3 
cells transduced with either empty vector (control), Vp16-ZF-119, Oct4 cDNA (positive control), KrAB-ZF-119, ZF-119 (no effector domain), ZF-119-Vp64, 
or ZF-119-Dnmt3a. Non-transformed HMEC cells were used as negative control for oct4 expression; Nt2/D1 and p86-otBC-L1 cells were used as 
positive control cancer cell lines expressing high levels of oct4. An anti-histone H3 antibody was used as loading control. the quantification of the 
bands of a representative western blot is shown in (F). the oct4 expression was normalized to the Nt2/D1 sample. (G) transduction of KrAB-ZF-119 
and Oct4 cDNA in oVCAr-3 cells results in induction of tumorsphere formation. representative images of the transfected cells are shown, outlining 
the morphological differences in the cells transfected with the KrAB-ZF-119 and Oct4 cDNA, which formed highly proliferative and compact spheroids. 
Control refers to empty-vector transduced cells. A quantification of the number of spheroids for each sample is shown in (H). Data representing three 
independent experiments was normalized to control-transduced cells. Statistical significance was analyzed by the Student’s t-test (***p < 0.0001;  
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The mechanism of action of KRAB-containing ZFPs as tran-
scriptional activators still remains elusive and will require fur-
ther investigation. KRAB-associated proteins could negatively 
interfere with repressive proteins, such as Histone deacetylases, 
Histone methyltransferases, DNA methyltransferase and other 
complexes. The ZF-119-binding site overlaps with a putative SP1 
binding site and with a HRE site, and it is possible that the engi-
neered protein could negatively affect the transcriptional activity 
of these endogenous proteins. Alternatively, KRAB-ZFPs may 
also function to facilitate the binding of TFs and co-activators 
into the targeted promoter. KRAB-ZF-119 could be regarded as 
a “pioneer transcription factor”:63 by binding into the proximal 
Oct4 promoter, KRAB-ZF-119 could directly (e.g., via direct 
recruitment) or indirectly (e.g., via local changes in chromatin 
structure) engage the access of Sox2 and/or other TFs in the Oct4 
promoter. Several ZFPs involved in the maintenance of a plu-
ripotent state, such as ZFP20641 and ZFP281,64 have been shown 
to physically interact with self-renewal TFs, such as Oct4, Sox2 
and Nanog. Similarly, KRAB-ZF-119 could physically interact 
with KRAB-associated factors and recruit TFs, co-activators 
example, one difference between OVCAR-3 and MDA-MB-231 
cells is the very high levels of Sox2 in OVCAR-3, which could 
prime or facilitate an activation state in the promoter. Finally, in 
the vast majority of cell lines analyzed re-activation of Oct4 by 
KRAB-ZF-119 was also accompanied by a significant upregula-
tion of the Oct4 downstream targets, such as Sox2 and Nanog, 
as expected from the auto-regulatory feedback-loop previously 
described between Oct4-Sox2-Nanog in ESCs.6 However, we 
cannot exclude that KRAB-ZF-119 could also be recruited to 
other promoters and thus ChIP-Seq data will be necessary to 
map all ZFP binding sites in the cancer cell genome.
The KRAB domain is particularly abundant in natural 
ZF TFs hence it has been mapped in the N-terminus of the 
DNA-binding domain in about one third of all C2H2 ZFPs. 
The KRAB domain spans ~75 amino acids present exclusively 
in vertebrates, and is composed of two boxes, A and B. One 
of the main co-repressors of KRAB is KRAB-Associated pro-
tein 1 (KAP-1), which interacts with box A.49 In the proposed 
model of repression, KAP-1 can recruit the chromatin modifier 
SETDB1, which directs H3K9me3.61 In addition, KAP1 also 
binds Heterochromatin protein 1 (HP1), which interacts with 
H3K9me3, stabilizing the repressive complex in chromatin. 
Recent genome-wide studies revealed that most KRAB-ZFPs 
recruit KAP-1 to the 3'-coding exons of ZF genes, and not to 
the gene promoters. It has been proposed that KAP-1 could be 
recruited to promoter sequences through interaction with other 
DNA-binding TFs.39,40
Although the function of KRAB as a repressor has been long 
described, recent genome-wide data from ChIP-Seq had demon-
strated that natural KRAB-ZFPs bind and activate certain cel-
lular targets. One example is the ZFP236, a TF that contains a 
N-terminal KRAB domain. While ZFP263 acts as a repressor 
for some cellular targets, the same protein binds and upregu-
lates other sets of cellular promoters, such as foxa1, itpka and 
rgs10.41 These data suggest that although ZFP containing KRAB 
domains function as transcriptional repressors, in some genomic 
contexts they can also act as activators. Our results are in agree-
ment with this new emerging function of KRAB-containing 
ZF proteins in gene activation. In addition, the reprogramming 
field has recently reported numerous examples ZFPs, including 
N-terminal KRAB or other repressor domains (such as SCAN 
domains) that participate in the upregulation of self-renewal gene 
promoters. One example is ZFP206 (Zscan10), a TF expressed 
in ES cells and an integral component of the self-renewal cir-
cuitry. The overexpression of ZFP206 activated transcription of 
some direct targets such as Oct4, Klf5 and Jarid1c, while repress-
ing the expression of others promoters, such as Meis2, mir-124-a 
and mir-124-a2.62 These results reinforce the idea that genomic 
context can affect the specificity and the regulatory poten-
tial of ZFPs. As with KRAB-domains, SCAN domains could 
also mediate context-dependent protein-protein interactions at 
genomic targets, resulting in either activation or repression. The 
particular composition of co-activators, co-repressors and epigen-
etic modifiers in targeted regulatory regions is potentially critical 
for the recruitment of ZFPs and for the regulatory outcome of 
these proteins.
Figure 4. KrAB-ZF-119 binds the endogenous Oct4 promoter and 
upregulates transcription. (A) Chromatin immunoprecipitation (Chip) to 
detect the binding of ZF-119 to its target site in SUM159 cells. An anti-HA 
antibody was used to capture the ZF-119 bound to its genomic target 
DNA from control-transduced cancer cells and cells transduced with ZF-
119. A quantification of the Chip assay by densitometric analyses of the 
bands from the same gel is outlined below. Data was normalized to the 
input signal. (B) Schematic representation of a proposed transcriptional 
activation model in the Oct4 gene promoter mediated by the KrAB 
domain. After KrAB-ZF-119 binds to the Oct4 gene promoter, the KrAB 
domain could recruit and/or facilitate the recruitment of a constellation 
of transcriptional activating factors including Sox2, enabling their ac-
cess and binding to the Oct4 promoter; alternatively the KrAB or KrAB-
associated factors could inhibit a transcriptional repressor complex in 
























cell lines MDA-MB-231, MDA-MB-435s, MDA-MB-453 and 
MDA-MB-468 were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 10% Fetal Bovine Serum 
(FBS, BenchMark, Gemini Bio Products) and 1% Penicillin/
Streptomycin (Pen/Strep, Invitrogen). Culture media of MDA-
MB-435s cells contained additionally 0.01 mg/ml Bovine 
Insulin (Gibco/Invitrogen). MCF7 breast cancer cells were 
cultured in Minimum Essential Media (MEM) supplemented 
with 1.5 g/l sodium bicarbonate, 0.1 mM non-essential amino 
acids (NEAAs), 1mM sodium pyruvate, 0.01 mg/ml Bovine 
Insulin, 10% FBS and 1% Pen/Strep. MCF7 cells were cul-
tured in DMEM containing 20 ng/ml Epithelial Growth Factor 
(EGF), 100 ng/ml cholera toxin, 00.1 mg/ml Bovine Insulin, 
500 ng/ml hydrocortisone, 5% Horse serum and 1% Pen/Strep. 
MDA-MB-468 breast cancer cells were cultured in L15 media 
supplemented with 10% FBS and 1% Pen/Strep. ZR-75-1 and 
BT549 cells were cultured in RPMI 1640 media supplemented 
with 10% FBS and 1% Pen/Strep. SUM102 and SUM149 cells 
were cultured in human mammary epithelial cell (HMEC) media 
containing HMEC supplemental bullet kit (Gibco/Invitrogen), 
bovine pituitary extract (Gibco/Invitrogen) and 1% Pen/Strep. 
For SUM149 cells, the media contained additionally 5% FBS. 
SUM159 breast cancer cells were cultured in Ham’s F12 media 
containing 5 mg/ml Bovine Insulin, 1 mg/ml hydrocortisone, 
10 mM Hepes, 5% FBS and 1% Pen/Strep. SK-Br-3 cells were 
cultured in McCoy’s 5a Medium, supplemented with 10% FBS 
and 1% Pen/Strep. MDA-MB-453s breast cancer cells were cul-
tured in Leibovitz’s L15 Medium, supplemented with 10% FBS 
and 1% Pen/Strep. Human ovarian cancer cell line OVCAR-3 
were culture in RPMI medium supplemented with 20% FBS and 
1% Pen/Strep. Human ovarian teratocarcinoma PA-1 cells were 
cultured in MEM α medium supplemented with 10% FBS and 
1% Pen/Strep. Human epithelial adenocarcinoma SKOV-3 cells 
were cultured in McCoy medium supplemented with 10% FBS 
and 1% Pen/Strep.
Ovarian cancer patient-derived samples. Primary and meta-
static ovarian cancer sections and peritoneal fluid (ascites) were 
obtained from the Pontificia Universidad Católica de Chile with 
written patient consent and approved IRB protocols. Ascites 
cells were grown in adherent tissue culture plates in DMEM/
F12 medium (Gibco/Invitrogen), containing 1% antibiotic/anti-
mitotic (Gibco/Invitrogen), 5% FBS (BenchMark, Gemini Bio 
Products).
RNA and DNA preparation. Cell cultures were harvested for 
RNA and DNA preparation before and after retroviral transduc-
tion. To purify total RNA, cell samples derived from patients 
were resuspended in Trizol reagent following the manufacturer’s 
instructions (Gibco/Invitrogen). Cell line culture samples were 
processed with the RNeasy kit (Qiagen) and processed for qRT-
PCR analyses as described below. A Puregene DNA Purification 
Kit (Gentra Systems) was used to purify DNA while genomic 
DNA was isolated using the DNeasy Tissue Kit (Qiagen).
Sodium bisulfite conversion and DNA methylation map-
ping in the Oct4 promoter by Sequenom EpiTYPER assay. The 
methylation status of 19 CpG dinucleotides within the human 
Oct4 gene promoter region was examined in bisulfide-modified 
and chromatin remodelers to activate targeted genes. For exam-
ple, KRAB-ZF-119 could recruit self-renewal TFs, such as 
Sox2, which is abundantly expressed in SOC cell lines, such as 
OVCAR-3 and PA-1. Further research is required to validate 
these models and to elucidate the exact mechanism of action of 
KRAB-ZFPs. Another interesting question for further study is 
whether TAL Effectors containing N-terminal KRAB domains 
are also subjected to the same regulatory outcomes as ZF-based 
ATFs. One difference between ZF proteins and TALE effectors is 
the size of the DNA binding domains, ZFs being more compact 
and particularly biased to recognize GC-rich sequences, which 
are abundant in proximal promoters. In conclusion, our data sup-
ports a new paradigm for KRAB-ZFPs and suggests that these 
proteins could function, in certain genomic loci, as activators of 
endogenous genes. These findings have important implications 
for investigators working within the areas of ZF protein biol-
ogy, genomic reprogramming, artificial gene regulation and cell 
engineering.
Materials and Methods
ATF construction. Target sites for ZF recognition within the 
Oct4 human proximal promoter (GenBank accession number 
AJ297527.1) were selected using the website www.zincfinger-
tools.org.65 ZF-119 was selected based on its close proximity 
to the translation start site and because the 18-bp site was per-
fectly conserved across vertebrate species, including human and 
mouse.46 Specific primers were designed to incorporate the amino 
acid residues in the ZF’s recognition helix of ZF-119, responsible 
for the binding to the target sequence. The 18-bp target site of 
ZF-119, shown in Figure 2A, is: 3'-GGG GGC GGG GCC AGA 
GGT-5' while the Oct4-ZF sequences are shown in Figure 2C. 
The ZF-119 DNA-binding domain was generated by overlapping 
PCR as previously described.31 The PCR fragments were digested 
with SfiI and sub-cloned into the retroviral vector pMX-IRES-
GFP containing different effector domains: a N-terminal VP16, 
a C-terminal VP64,31 a N-terminal Dnmt3a,38 a C-terminal 
Dnmt3a38 and a N-terminal KRAB,37 producing the following 
ATFs: pMX-VP16-ZF119, pMX-ZF119-VP64, pMX-Dnmt3a-
ZF119, pMX-ZF119-Dnmt3a and pMX-KRAB-ZF119. Each 
ATF contains an internal SV40 nuclear localization signal (NLS) 
and a terminal hemagglutinin (HA) decapeptide tag. Plasmid 
sequencing was performed to confirm the correct nucleotide 
sequence of each ATF construct.
Cell lines and cell culture. Human breast cancer cell lines 
SUM102, SUM149, SUM159, MCF7, MCF12A, MDA-MB-231, 
MDA-MB-435s, MDA-MB-453, MDA-MB-468, ZR-75-1 and 
BT-543 were obtained from the Core Tissue Culture Facility 
of the UNC Lineberger Comprehensive Cancer Center. The 
cell line p86-OTBC-L1 was isolated previously by our group.12 
The packaging cell line 293TGagPol and the human testicu-
lar embryonic carcinoma cell line NT2/D1 were obtained 
from the American Type Culture Collection (ATCC). Cell 
lines were propagated in growth medium as specified by the 
ATCC and maintained at 37°C and 5% CO
2
. The packaging 
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anti-rabbit (1:5000, GE Healthcare). Western blotting detection 
was performed with the Amersham ECL Detection System (GE 
Healthcare). Western blots were quantitated using the program 
Image J v1.46 (ImageJ, NCBI). Expression of Oct4 protein in 
each cell preparation was normalized to the NT2/D1 cell line.
Immunoprecipitation of the ZF fusions. MDA-MB-231 cells 
were retrovirally transfected as previously described. Forty-eight 
hours post-transfection, cells were collected and total protein 
extract isolated with Radioimmunoprecipitation Assay Buffer 
(RIPA buffer; Sigma-Aldrich). Protein lysates (500 μg) were 
pre-incubated with 1 μg of anti-HA antibody (Covance) for 
2 h at 4°C and 40 μl of protein A/protein G beads were added to 
each sample and incubated in constant agitation for 24 h. Samples 
were collected by centrifugation at 3,000 rpm (~1,000 × g) for 
30 sec at 4°C. Supernatant was discarded and pellet was gently 
washed 4 times with 1ml of RIPA buffer, followed of 4 rinse steps 
with 1× PBS buffer. After the final rinse, beads were resuspended 
in 40 μl of 2× electrophoresis sample buffer (Santa Cruz 24945) 
and resolved on 12% SDS-PAGE gel. Immunodetection was per-
formed with an anti-HA antibody (Covance).
Chromatin immunoprecipitation (ChIP). ChIP assay was 
performed to detect the ZF-119 binding to the human Oct4 
gene promoter in vivo. Briefly, ~107 SUM159 cells were trans-
duced with either control (empty retroviral vector) or ZF-116. 
Protein-DNA complexes were pulled-down with protein A/pro-
tein G beads coupled with anti-HA antibody (Covance). After 
incubation, the beads were washed out three times with low-salt 
buffer, three times with high-salt buffer and two times with Tris-
EDTA buffer. The DNA was eluted from the beads by incubat-
ing them overnight at 65°C with an elution buffer (Tris-EDTA 
buffer, 1% SDS and 2 μl of Proteinase K). DNA was purified 
by phenol/chloroform-extraction procedure. The immunopre-
cipitated DNA was amplified by PCR, using the following prim-
ers flanking the ZF-119 binding site in the Oct4 gene promoter: 
5'-ACC ATT AGG CAA ACA TCC TT-3' (forward primer) and 
5'-GGG GAA GGA AGG CGC CCC-3' (reverse primer). As 
control for PCR amplifications the house-keeping gene GAPDH 
was used with the following primers: 5'-TAC TCG CGG CTT 
TAC GGG-3' and 5'-TGG AAC AGG GAG GAG CAG AGA 
GCA-3'. PCR products were visualized by agarose gel electro-
phoresis and the relative fold enrichment determined by densi-
tometry (ImageJ, NCBI) and normalized to the input samples.
Immunofluorescence. Fibroblast, HMEC, MDA-MB-231, 
OVCAR-3, PA-1 and p86-OTBC-L1 cells were seeded in fibro-
nectin-coated coverslips and fixed with 4% formaldehyde-PBS 
solution at room temperature for 10 min. Cells were permeabi-
lized with 0.3% Triton X/PBS for 15 min at 4°C and 5% BSA/
PBS was added for overnight blocking at 4°C. Fibronectin, form-
aldehyde and Triton-X were purchased from Sigma. Cells were 
incubated at 4°C overnight with primary rabbit anti-Oct4 anti-
body (Abcam) diluted 1:250 in 1% BSA/PBS. After the incu-
bation, the slides were rinsed and labeled with the secondary 
antibody Alexa 555 anti-rabbit IgG in a 1:1,000 dilution (Gibco/
Invitrogen). Nuclear staining was visualized with DAPI or 
Hoechst dye (Gibco/Invitrogen). Intracellular expression of Oct4 
was detected using a Zeiss 510 Meta Inverted Laser Scanning 
DNA as previously described.38 Genomic DNA (1.5 μg) iso-
lated from un-transduced cell line samples (Fibroblast, HMEC, 
MDA-MB-231, OVCAR-3, PA-1 and p86-OTBC-L1) was modi-
fied using the EZ DNA Methylation-Gold Kit (Zymo Research). 
Samples were further purified with the Wizard DNA purification 
resin (Promega) and resuspended in water. Bisulfite converted 
DNA was processed using a Sequenom EpiTYPER platform 
at the Yale Center for Genome Analysis (Yale University). The 
primers used for the amplification of converted DNA were: 
Oct4-amp1-F (forward primer): TAG TTG GGA TGT GTA 
GAG TTT GAG A; Oct4-amp1-R (reverse primer): TAA ACC 
AAA ACA ATC CTT CTA CTC C; Oct4-amp8-F: GGA GTA 
GAA GGA TTG TTT TGG TTT A; Oct4-amp8-R: ATC ACC 
TCC ACC ACC TAA AAA A; Oct4-amp14-F: TTT ATT ATT 
TTT ATT ATT TGG AGG GGG; Oct4-amp14-R: CAA TAA 
TCC AAA CCT ATA ATC CCA A.
ATF retroviral transduction. The retroviral vector pMX-
IRES-GFP containing the Oct4 ATFs (pMX-ZF119-VP16, 
pMX-ZF119-VP64, pMX-ZF119-Dnmt3a, pMX-Dnmt3a-
ZF119 or pMX-ZF119-KRAB) was first co-transfected with 
the pMDG.1 plasmid, expressing the vesicular stomatitis virus 
envelope protein into the packing 293TGag-Pol cells to pro-
duce retroviral particles. Transfection was performed using 
Lipofectamine according with the manufacturer’s instructions 
(Gibco/Invitrogen). The viral supernatant was collected and 
used to infect the host cell lines. Transfected cells were incubated 
at 37°C in 5% CO
2
 for 4 d, and collected for RNA, DNA or 
protein extracts. The RNA was extracted, reverse transcribed and 
processed for real-time quantification of Oct4 mRNA expression.
Quantitative real-time PCR. RNA from cell line cultures 
and patient-derived samples was extracted as mentioned above 
according to the manufacturer’s recommendations and reverse-
transcribed to cDNA using the High Capacity cDNA reverse 
transcription kit (Applied Biosystems). For qRT-PCR assays, 
reactions were performed with a final concentration of 1× of 
TaqMan Fast Universal Master Mix (Applied Biosystems) and 
150 ng of cDNA. Primers used for qRT-PCR assays are described 
by Beltran et al.12 qRT-PCR data was analyzed with the 7500 
Software Version 2.0.5, using the comparative ΔCt method and 
GAPDH as an endogenous reporter gene (AB Prism software, 
Applied Biosystems). The results were plotted as the average of 
at least 3 independent experiments with duplicates, and standard 
errors calculated using GraphPad Prism v5 software. Fold-Oct4 
mRNA levels were calculated relative to the fibroblast sample or, 
for transduced experiments, to the control cells (cells transduced 
with an empty retroviral vector, when indicated). Statistical dif-
ferences between groups were determined by Student’s t-test.
Western blotting. Total protein extract was obtained with 
Radioimmunoprecipitation Assay Buffer (RIPA buffer; Sigma-
Aldrich). Nuclear protein extraction was performed using the 
NE-PER Nuclear and Cytoplasmic Extraction Kit (Pierce 
Biotechnology). Protein lysates (50 μg) were resolved on 12% 
SDS-PAGE gels. Antibodies included: rabbit anti-Oct4 (Abcam) 
diluted at 1:250; anti-Tubulin (Sigma-Aldrich) diluted 1:5,000; 
anti-H3 (Active Motif) diluted 1:10,000, and horseradish per-
























was plotted and normalized to OVCAR-3 cells transfected 
with an empty vector (control). Statistical differences between 
groups were determined by Student’s t-test (***p < 0.0001; 
**p ≤ 0.01; *p ≤ 0.05).
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Confocal Microscope at the Michael Hooker Microscopy Facility 
at UNC.
Immunohistochemistry (IHC)/Chromogenic detection of 
Oct4 in breast/ovarian cancer specimens. IHC was performed 
in the Bond Autostainer (Leica Microsystems Inc.). Briefly, slides 
were dewaxed in Bond Dewax solution (AR9222) and hydrated 
in Bond Wash solution (AR9590). Antigen retrieval was per-
formed for 30 min at 100°C in Bond-Epitope Retrieval solu-
tion 1 pH-6.0 (AR9961) and blocked with Dako Serum-Free 
Ready-To-Use Protein Block for 10 min (X0909). Slides were 
incubated with an anti-Oct4 antibody (ab18976 Abcam) for 
2 h. Antibody detection was performed using the Bond Polymer 
Refine Detection System (DS9800). Stained slides were dehy-
drated and coverslipped. Stained slides were imaged using the 
Aperio Scanscope XT (Aperio Technologies). Images were exam-
ined using Spectrum digital pathology platform.
Tumorsphere assay. OVCAR-3 cells were transfected with 
control, KRAB-ZF-119 or Oct4 cDNA retroviral vectors as 
described above. Seventy-two hours post-transfection 20,000 
cells were seeded in triplicate wells, in a 6-well plate (low adherent 
plates) in spheroid media: HMEC medium (Gibco/Invitrogen) 
containing 20 ng/ml human EGF (BD Biosciences), 1 μg/ml 
hydrocortisone (Stem Cell Technologies), insulin 5 μg/ml 
(Sigma) and 1 × B27 (Gibco/Invitrogen). The plates were incu-
bated at 37°C in 5% CO
2
. Tumorspheres were visualized using a 
cell culture Leica microscope 3 d after seeding. Tumorspheres were 
counted and the mean ± SD of three independent experiments 
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